Wedbush Securities’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Wedbush Securities’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,011	Closed	-$214K	–	1227
2021 Q4	$214K	Sell	6,011 -3,495	-37%	-$131K	0.01%	1037
2021 Q3	$390K	Buy	+9,506	New	+$401K	0.02%	722
2020 Q4	–	Sell	-13,924	Closed	-$385K	–	1006
2020 Q3	$385K	Buy	13,924 +4,984	+56%	+$147K	0.04%	510
2020 Q2	$255K	Buy	+8,940	New	+$241K	0.02%	667

Other funds holding GERM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wedbush Securities's GERM Position: Q1 2022 in Review

Wedbush Securities sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2022, closing a stake of 6,011 shares — an estimated $214K sold.

Wedbush Securities first reported a position in GERM in Q2 2020 and held it in 4 quarters. The position peaked at $390K in Q3 2021. 28 funds tracked by Wall St. Rank hold GERM as of Q1 2022.

Wedbush Securities reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2022 after selling out during the quarter.
Wedbush Securities sold 6,011 Amplify Treatments, Testing and Advancements ETF shares in Q1 2022, an estimated $214K.
Wedbush Securities first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2020 and held it in 4 quarters.
Wedbush Securities's Amplify Treatments, Testing and Advancements ETF position peaked at $390K in Q3 2021.
28 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2022.

Based on Wedbush Securities's 13F filing for Q1 2022, filed 19 Apr 2022.